


CLAIMS


1. A combination of a glycine/NMDA antagonist and a tachykinin
NK-1 receptor antagonist for simultaneous, separate or sequential use in
5 the treatment of neurodegeneration.

2. A combination as defined in claim 1 wherein the glycine/NMDA
antagonist is:



UK-240,455

or



UK-333,747.

10

3. A combination as defined in claim 2 wherein the glycine/NMDA
antagonist is UK-240,455.

15 4. A combination as defined in claim 2 wherein the glycine/NMDA
antagonist is UK-333,747.

5. A combination as defined in any previous claim wherein the tachykinin NK-1 receptor antagonist is aprepitant [2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine].

5

6. A pharmaceutical composition comprising a combination as defined in any previous claim in association with a pharmaceutically acceptable carrier.

10 7. The use of a combination as defined in any one of claims 1 to 5 for the manufacture of a medicament for the treatment of neurodegeneration.

8. A method for the treatment of neurodegeneration which comprises administering to a patient in need of such treatment a combination as
15 defined in claim 1.